Our Pipeline
Polygen generic product pipeline represents a comprehensive focus across multiple therapeutic areas and dosage forms. Polygen’s generic pipeline consists of different products in various stages of development, filed and awaiting U.S. FDA approval.
Polygen product pipeline covers broad therapeutic areas including Antihyperlipidemic, Alzheimer’s dementia, Anorectic, Estrogen receptor modulator, Skeletal Muscle Relaxant, anti-epileptic and Antispasmodic
| Product | Status | Anticipated Filing |
| A | Under review at FDA | ANDA filed |
| B | Under review at FDA | ANDA filed |
| C | Development & Scale up Complete | Second Quarter 2017 |
| D | Development & Scale up Complete | Second Quarter 2017 |
| E | Development & Scale up Complete | Second Quarter 2017 |
| F | Under Development | Third Quarter 2017 |
| G | Under Development | Third Quarter 2017 |
| H | Under Development | Third Quarter 2017 |
ANDA Approved Products
ANDA 207821 Amlodipine Besylate Tablets (2.5, 5.0 & 10mg)
ANDA 206342 Phentermine Hydrochloride Tablets (37.5 mg)
